Plasma Proteomic Profiling Identifies a Six-Protein Panel for Grading and Predicting Intervertebral Disc Degeneration

Area of Science:

• Biochemistry
• Proteomics
• Biomarker Discovery

Background:

• Intervertebral disc degeneration (IDD) is a major cause of chronic pain and disability.
• Current understanding of IDD's biological mechanisms and early diagnostic biomarkers is limited.
• Proteomics offers potential for identifying blood-based biomarkers for IDD.

Purpose of the Study:

• To identify and validate specific plasma proteins associated with different grades of IDD.
• To discover noninvasive biomarkers for early diagnosis of intervertebral disc degeneration.
• To assess differential protein expression in plasma samples from IDD patients.

Main Methods:

• Case-control study comparing plasma from Grade II and Grade V IDD patients.
• Proteomic analysis using the SomaScan Assay to identify candidate proteins.
• Enzyme-linked immunosorbent assay (ELISA) for biomarker validation in a larger cohort.

Main Results:

• Six differential proteins (COL6α3, REG1β, ATF5, CAP1, MAGEA4, LILRB3) were identified as potential biomarkers.
• A combined six-protein model demonstrated high predictive efficacy (AUC = 0.8700).
• Validated plasma biomarkers offer a noninvasive approach for IDD diagnosis.

Conclusions:

• Identified plasma proteins serve as novel, noninvasive biomarkers for early IDD detection.
• These biomarkers can facilitate timely diagnosis and potentially improve therapeutic strategies.
• The findings advance the understanding of IDD's molecular pathology and diagnostics.